|Bid||9.76 x 1100|
|Ask||9.78 x 900|
|Day's range||9.53 - 10.46|
|52-week range||4.23 - 37.99|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.50|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
COVID-19 testing company Lucira Health became public only in February, but it has been plagued by problems since. Lucira's flagship device is a single-use, do-it-yourself COVID-19 test kit that received regulatory clearance for over-the-counter use in April. Overall, it was a major innovation by Lucira Health, but it came a tad bit too late.
Although the pandemic has mostly faded from the front pages, mutations of the SARS-CoV-2 virus are increasing the odds that COVID will make a resurgence this winter. Add in many Americans' hesitancy over vaccines, and it appears the companies providing testing, treatments, and vaccine boosters could remain a part of our lives longer than it seemed only a few months ago. Revenue rose 1,200% on the back of a 74-fold increase in testing volume.